Alkermes $ALKS buying Avadel $AVDL for up to $20 per share. Deal value $2.1B

$ALKS $TAK orexin data presentations from the sleep meeting in Singapore. Alkermes, Takeda show encouraging data on narcolepsy drugs https://t.co/TJtEk9EgeB via @elaineywchen
Drugmakers are racing to help patients stay awake — and could also make billions A great read from my colleague @elaineywchen reporting on the development of orexin inhibitors $ALKS $CNTA $TAK Link below...
Alkermes $ALKS drug helped narcolepsy patients stay awake in Phase 2 trial https://t.co/DpzjXfK3n8 More orexin results but no numbers for now. via @elaineywchen